Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is a promising company with a strong focus on developing and commercializing treatment for CNS diseases, including its promising drug candidate Roluperidone for schizophrenia patients. With positive results from Phase 2b and 3 trials and a planned Phase 3 trial with potential FDA approval in 2029, the market potential for this drug and the company is high. However, there are potential risks and challenges, such as the need for additional funding and securing accurate trial data.

Bears say

Minerva Neurosciences is facing significant clinical risk as their current candidate, Roluperidone, could fail to meet efficacy endpoints or may produce safety signals that impair approval and/or commercialization. With a fully diluted share count of ~111 million shares, the company's $14 price target is derived from a DCF analysis including a 12% discount rate, which is consistent with other development-stage companies. In addition, Minerva ended 2025 with cash and equivalents of ~$82 million, making it necessary for the company to secure further financing in order to continue its operations and commercialization efforts.

Minerva Neurosciences (NERV) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Hold based on their latest research and market trends.

According to 2 analysts, Minerva Neurosciences (NERV) has a Hold consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.